异麦芽糖酐铁治疗肿瘤相关性贫血的疗效分析  

Analysis of the efficacy of iron isomaltose in the treatment of tumor-related anemia

作　　者：苏铎峰 安宁 熊丽[1] SU Duo-feng;AN Ning;XIONG Li(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,China;Oncology Department,Sichuan Academy of Medical Science&Sichuan Provincial People’s Hospital(Affiliated Hospital of University of Electronic Science and Technology of China),Chengdu 610072,China)

机构地区：[1]电子科技大学医学院,四川成都610054 [2]四川省医学科学院·四川省人民医院(电子科技大学附属医院),四川成都610072

出　　处：《实用医院临床杂志》2025年第2期126-130,共5页Practical Journal of Clinical Medicine

基　　金：四川省医学会专项科研项目(编号:2024HR41)。

摘　　要：目的评估异麦芽糖酐铁纠正肿瘤相关性贫血的临床疗效。方法回顾性分析2022年4月至2024年1月在四川省人民医院经诊断与治疗的肿瘤相关性贫血患者157例,其中观察组为采用异麦芽糖酐铁治疗者76例,对照组为采用多糖铁复合物治疗者81例,记录治疗前后两组患者的血红蛋白(Hb)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)和血清铁(SI)浓度,比较两组患者治疗后相关贫血指标变化,评估异麦芽糖酐铁治疗后肿瘤相关性贫血患者的贫血改善程度及其影响因素。结果治疗4周后两组患者Hb、SF、TSAT、SI水平均高于治疗前(P<0.05),且观察组明显高于对照组(P<0.05);观察组治疗有效60例(78.95%),其中贫血程度为中度、铁缺乏类别为绝对性铁缺乏的占比明显高于治疗无效患者(P<0.05)。结论相较于多糖铁复合物,异麦芽糖酐铁更能有效提高肿瘤患者血红蛋白水平;不同贫血程度及铁缺乏类别会影响异麦芽糖酐铁在肿瘤相关性贫血中的疗效,中度贫血及绝对性铁缺乏的患者疗效更显著。Objective To evaluate the clinical efficacy of iron isomaltoside in the treatment of cancer related anemia.Methods A retrospective analysis was performed on 157 patients with cancer related anemia diagnosed and treated in our hospital from April 2022 to January 2024.The patients were divided into an observation group(n=76)and a control group(n=81).The observation group was treated with iron isomaltoside for anemia.The control group was treated with iron polysaccharide complex for anemia.Hemoglobin(Hb),serum ferritin(SF),transferrin saturation(TSAT),and serum iron(SI)concentrations of the two groups were recorded before and after treatment.Changes in anemia-related indicators were compared between the two groups after treatment.The degree of anemia improvement and its influencing factors were evaluated.Results After 4 weeks of treatment,the levels of Hb,SF,TSAT,and SI in both groups were higher than those before treatment(P<0.05),and the observation group was significantly higher than the control group(P<0.05).In the observation group,60 patients(78.95%)responded effectively to the treatment.Among them,the proportions of patients with moderate anemia and those with absolute iron deficiency were significantly higher than those in patients who did not respond to the treatment(P<0.05).Conclusions Compared with iron polysaccharide complex,iron isomaltoside can more effectively increase the hemoglobin level of tumor patients.Different anemia degrees and iron deficiency types will affect the efficacy of iron isomaltose in tumor-related anemia.The efficacy is more significant in patients with moderate anemia and absolute iron deficiency.

关 键 词：异麦芽糖酐铁 肿瘤 贫血 

分 类 号：R730.6[医药卫生—肿瘤]